Famciclovir
Active ingredient: Famciclovir
In short: Herpes labialis (cold sores):Famciclovir tablets are indicated for the treatment of recurrent herpes labialis in adult patients. Genital herpes: Recurrent episodes:Famciclovir tablets are indicated for the treatment of recurrent episodes of genital herpes.
What is Famciclovir used for?
Herpes labialis (cold sores):Famciclovir tablets are indicated for the treatment of recurrent herpes labialis in adult patients.
Genital herpes:
Recurrent episodes:Famciclovir tablets are indicated for the treatment of recurrent episodes of genital herpes. The efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions has not been established.
Suppressive therapy:Famciclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in adult patients. The efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established.
Herpes zoster (shingles):Famciclovir tablets are indicated for the treatment of herpes zoster in adult patients. The efficacy of famciclovir tablets when initiated more than 72 hours after onset of rash has not been established.
Recurrent orolabial or genital herpes: Famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected adults. The efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established. …
Famciclovir dosage
Famciclovir tablets may be taken with or without food.
Herpes labialis (cold sores):The recommended dosage of famciclovir tablets for the treatment of recurrent herpes labialis is 1500 mg as a single dose. Therapy should be initiated at the first sign or symptom of herpes labialis (e.g., tingling, itching, burning, pain, or lesion).
Genital herpes:
Recurrent episodes:The recommended dosage of famciclovir tablets for the treatment of recurrent episodes of genital herpes is 1000 mg twice daily for 1 day. Therapy should be initiated at the first sign or symptom of a recurrent episode (e.g., tingling, itching, burning, pain, or lesion).
Suppressive therapy:The recommended dosage of famciclovir tablets for chronic suppressive therapy of recurrent episodes of genital herpes is 250 mg twice daily.
Herpes zoster (shingles):The recommended dosage of famciclovir tablets for the treatment of herpes zoster is 500 mg every 8 hours for 7 days. Therapy should be initiated as soon as herpes zoster is diagnosed.
Recurrent orolabial or genital herpes:The recommended dosage of famciclovir tablets for the treatment of recurrent orolabial or genital herpes in HIV-infected patients is 500 mg twice daily for 7 days. Therapy should be initiated at the first sign or symptom of a recurrent episode (e.g., tingling, itching, burning, pain, or lesion).
Dosage recommendations for adult patients with renal impairment are provided in Table 1
.
Table 1: Dosage Recommendations for Adult Patients with Renal Impairment
Indication and Normal Dosage Regimen | Creatinine Clearance (mL/min) | Adjusted Dosage
Regimen Dose (mg) | Dosing Interval
Single-Day Dosing Regimens
Recurrent Genital Herpes
1000 mg every 12 hours for1 day | ≥60 | 1000 | every 12 hours for 1 day
40-59 | 500 | every 12 hours for 1 day
20-39 | 500 | single dose
<20 | 250 | single dose
HD* | 250 | single dose following dialysis
Recurrent Herpes Labialis
1500 mg single dose | ≥60 | 1500 | single dose
40-59 | 750 | single dose
20-39 | 500 | single dose
<20 | 250 | single dose
HD* | 250 | single dose following dialysis
Multiple-Day Dosing Regimens
Herpes Zoster
500 mg every 8 hours | ≥60 | 500 | every 8 hours
40-59 | 500 | every 12 hours
20-39 | 500 | every 24 hours
<20 | 250 | every 24 hours
HD* | 250 | following each dialysis
Suppression of Recurrent
Genital Herpes
250 mg every 12 hours | ≥40 | 250 | every 12 hours
20-39 | 125 | every 12 hours
<20 | 125 | every 24 hours
HD* | 125 | following each dialysis
Recurrent Orolabial or Genital Herpes in HIV-Infected Patients
500 mg every 12 hours | ≥40 | 500 | every 12 hours
20-39 | 500 | every 24 hours
<20 | 250 | every 24 hours
HD* | 250 | following each dialysis
*Hemodialysis
How to take Famciclovir — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
There is no evidence that famciclovir will affect the ability of a patient to drive or to use machines. However, patients who experience dizziness, somnolence, confusion or other central nervous system disturbances while taking famciclovir should refrain from driving or operating machinery.
Because famciclovir contains lactose (famciclovir 125 mg, 250 mg and 500 mg tablets contain lactose 23.5 mg, 47.1 mg and 94.2 mg, respectively), patients with rare hereditary problems of galactose intolerance, a severe lactase deficiency or glucose-galactose malabsorption should be advised to discuss with their healthcare provider before taking famciclovir.
Herpes Labialis (Cold Sores)
Patients should be advised to initiate treatment at the earliest sign or symptom of a recurrence of cold sores (e.g., tingling, itching, burning, pain, or lesion). Patients should be instructed that treatment for cold sores should not exceed 1 dose. Patients should be informed that famciclovir is not a cure for cold sores.
Genital Herpes
Patients should be informed that famciclovir is not a cure for genital herpes. …
Warnings & precautions
Do not take this medicine if: Famciclovir tablets are contraindicated in patients with known hypersensitivity to the product, its components, or Denavir
®(penciclovir cream).
Cases of acute renal failure have been reported in patients with underlying renal disease who have received inappropriately high doses of famciclovir for their level of renal function. Dosage reduction is recommended when administering famciclovir to patients with renal impairment
.
Famciclovir side effects
Acute renal failure is discussed in greater detail in other sections of the label
.
The most common adverse events reported in at least 1 indication by greater than 10% of adult patients treated with famciclovir are headache and nausea.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Immunocompetent patients: The safety of famciclovir has been evaluated in active- and placebo-controlled clinical studies involving 816 famciclovir-treated patients with herpes zoster (famciclovir, 250 mg three times daily to 750 mg three times daily), 163 famciclovir-treated patients with recurrent genital herpes (Famciclovir, 1000 mg twice daily); 1,197 patients with recurrent genital herpes treated with famciclovir as suppressive therapy (125 mg once daily to 250 mg three times daily) of which 570 patients received famciclovir (open-labeled and/or double-blind) for at least 10 months; and 447 famciclovir-treated patients with herpes labialis (Famciclovir, 1500 mg once daily or 750 mg twice daily). Table 2 lists selected adverse events. …
Drug interactions
The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily). No clinically significant effect on the pharmacokinetics of zidovudine, its metabolite zidovudine glucuronide, or emtricitabine was observed following a single oral dose of 500 mg famciclovir coadministered with zidovudine or emtricitabine.
An
in vitrostudy using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4enzymes.
No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. No clinically significant effect on penciclovir pharmacokinetics was observed following multiple-dose (three times daily) administration of famciclovir (500 mg) with multiple doses of digoxin.
Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir. …
About this medicine
The active ingredient in famciclovir tablets is famciclovir, USP, an orally administered prodrug of the antiviral agent penciclovir. Chemically, famciclovir, USP is known as 2-[2-(2-amino-9
H-purin-9-yl) ethyl]-1,3-propanediol diacetate. Its molecular formula is C
14H
19N
5O
4; its molecular weight is 321.3. It is a synthetic acyclic guanine derivative and has the following structure
Famciclovir, USP is a white to pale yellow solid. It is freely soluble in acetone and methanol, and sparingly soluble in ethanol and isopropanol. At 25°C famciclovir, USP is freely soluble (greater than 25% w/v) in water initially, but rapidly precipitates as the sparingly soluble (2% to 3% w/v) monohydrate. Famciclovir, USP is not hygroscopic below 85% relative humidity. Partition coefficients are: octanol/water (pH 4.8) P=1.09 and octanol/phosphate buffer (pH 7.4) P=2.08.
Famciclovir tablets contain 125 mg, 250 mg or 500 mg of famciclovir, USP, together with the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, magnesium stearate and sodium starch glycolate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5723f50e-b0fa-65f0-e063-6294a90a350f. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin